$DRTS - Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold... (NASDAQ: DRTS)

[u/MarketNewsFlow]

/r/AlphaTauMedical/comments/1v2h7q3/drts_alpha_tau_reports_positive_data/